黄金城集团

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Synthetic High-Density Lipoprotein-Based Nanomedicine to Silence SOCS1 in Tumor Microenvironment and Trigger Antitumor Immunity against Glioma

Angew Chem Int Ed Engl . . 2023-12; 
Chunrong Yang , Yujie Li , Yuchen Yang , Qiankun Ni , Zeyu Zhang , Yi Chai , Jinghong Li
Products/Services Used Details Operation
Peptide Synthesis The proteins were resolved in 4-12% Bis-Tris SurePAGE gel (Genscript, M00653)/EphA2671-679 and ApoA-1 mimetic peptides 22A were synthesized by GenScript. Get A Quote

摘要

Immunotherapies have shed light on the treatment of many cancers, but have not improved the outcomes of glioma (GBM). Here, we demonstrated that suppressor of cytokine signaling 1 (SOCS1) was associated with the GBM-associated immunosuppression and developed a multifunctional nanomedicine, which silenced SOCS1 in the tumor microenvironment (TME) of GBM and triggered strong antitumor immunity against GBM. Synthetic high-density lipoprotein (sHDL) was selected as the nanocarrier and a peptide was used to facilitate the blood-brain-barrier (BBB) penetration. The nanocarrier was loaded with a small interfering RNA (siRNA), a peptide, and an adjuvant to trigger antitumor immunity. The nanomedicine concentrated on th... More

关键词

Glioma; Nanomedicine; SOCS1; Tumor Microenvironment.